1428576-32-2

Basic information

• Product Name: tert-butyl 4-(4-(5-amino-2-(2-fluoro-5-methylphenyl)thiazole-4-carboxamido)-1-methyl-1H-pyrazol-5-yl)-6,6-difluoro-1,4-diazepane-1-carboxylate
• Synonyms: tert-butyl 4-(4-(5-amino-2-(2-fluoro-5-methylphenyl)thiazole-4-carboxamido)-1-methyl-1H-pyrazol-5-yl)-6,6-difluoro-1,4-diazepane-1-carboxylate
• CAS NO: 1428576-32-2
• Molecular Weight: 565.62
• Mol File: 1428576-32-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-(4-(5-amino-2-(2-fluoro-5-methylphenyl)thiazole-4-carboxamido)-1-methyl-1H-pyrazol-5-yl)-6,6-difluoro-1,4-diazepane-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(4-(5-amino-2-(2-fluoro-5-methylphenyl)thiazole-4-carboxamido)-1-methyl-1H-pyrazol-5-yl)-6,6-difluoro-1,4-diazepane-1-carboxylate(1428576-32-2)
• EPA Substance Registry System: tert-butyl 4-(4-(5-amino-2-(2-fluoro-5-methylphenyl)thiazole-4-carboxamido)-1-methyl-1H-pyrazol-5-yl)-6,6-difluoro-1,4-diazepane-1-carboxylate(1428576-32-2)

Safety Data

• Hazardous Substances Data: 1428576-32-2(Hazardous Substances Data)

Upstream product

• 1428573-87-8 tert-butyl 6,6-difluoro-4-(1-methyl-4-nitro-1H-pyrazol-5-yl)-1,4-diazepane-1-carboxylate 
• 1428573-90-3 tert-butyl 4-(4-(2-bromo-5-(tert-butoxycarbonylamino)thiazole-4-carboxamido)-1-methyl-1H-pyrazol-5-yl)-6,6-difluoro-1,4-diazepane-1-carboxylate 
• 166328-16-1 (2-fluoro-5-methylphenyl)boronic acid 

Downstream Products

• 1428569-47-4 5-amino-N-(5-(6,6-difluoro-1,4-diazepan-1-yl)-1-methyl-1H-pyrazol-4-yl)-2-(2-fluoro-5-methylphenyl)thiazole-4-carboxamide 

Relevant articles and documents

PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE

Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.